$IBRX

ImmunityBio has begun treating the first patients in Europe with ANKTIVA® plus BCG for BCG-unresponsive non-muscle invasive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar are supporting commercialization and distribution efforts across Europe.

Sellas (SLS) fell 17.2% this week after a key trial milestone. ImmunityBio (IBRX) declined despite FDA approvals. Ionis (IOVA) also slumped. SLS CEO called the milestone critical, but results are pending. IBRX has a Q4 FDA submission planned. Retail sentiment varied; all three stocks outperformed XBI this year.

ImmunityBio Inc. received FDA approval for expanded use of Anktiva to treat a more common form of bladder cancer, months ahead of schedule. The stock rose 4% on the news but has since fallen. Anktiva was initially approved in April 2024 for a rare form of bladder cancer. The FDA had rejected an earlier expanded use application but approved it in October 2024.

ImmunityBio (NASDAQ:IBRX) completed database lock for Cohort A of its QUILT-2.005 trial, evaluating ANKTIVA with BCG vs. BCG alone in BCG-naïve bladder cancer patients. Interim analysis showed longer complete response duration with the combination. Final results and FDA submission expected in Q4 2026. The trial enrolled 366 patients across 110 sites.

Disc Medicine (IRON) surged 38.86% to $78.93, leading healthcare gains. Cleveland-Cliffs (CLF) rose 16.34% to $14.10 in materials. Almonty Industries (ALM) fell 10.17% to $8.83, among notable decliners.

ImmunityBio reported 3-year data in the Journal of Urology for ANKTIVA plus BCG in BCG-unresponsive NMIBC, showing 84% cystectomy avoidance and mostly Grade 1–2 adverse events. The data confirms durability for the FDA-approved therapy.

U.S. stock indexes fell Wednesday after higher-than-expected inflation data raised Fed rate hike concerns. The Nasdaq Composite dropped 1.88%, while the Dow and S&P 500 declined 0.09% and 1.11%, respectively. Semiconductor stocks were hit hard, with Nvidia (NVDA) down 3% and the SOXX ETF falling 4.5%. CoreWeave (CRWV) and Nebius (NBIS) also declined over 15% and 10% respectively, due to a Gartner report on neoclouds. ImmunityBio (IBRX) rose after FDA approval of its drug Anktiva.

ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NEWS RELEASE FDA Expands ANKTIVA ® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease • Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), i

The FDA expanded approval of ImmunityBio's Anktiva for BCG-unresponsive bladder cancer that hasn't spread into the bladder muscle, based on earlier evidence. According to the company, this expands its use in bladder cancer treatment. (IBRX)

Congresswoman Lisa McClain reported stock transactions, including purchases of CACI International (NYSE:CACI) and Microsoft (NASDAQ:MSFT) valued between $15,001 and $50,000. CACI, a defense contractor, has a market cap of $13.6B and a 20% return over the past year. McClain also invested in several other stocks and partially sold Seagate Technology (NASDAQ:STX) shares.